Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
AIMS: In primary prevention, the adipocytokine adiponectin seems to be protective against diabetes mellitus and cardiovascular disease. Data in patients with manifest coronary artery disease (CAD) are scant stimulating the investigation of the association of adiponectin concentrations and cardiovascular outcome in a prospective CAD cohort. METHODS AND RESULTS: In 1890 consecutive patients with documented CAD [1130 with stable angina (SAP) and 760 with acute coronary syndrome (ACS)] baseline concentrations of adiponectin were measured by enzyme-linked immuno assay. During a median follow-up of 2.5 years cardiovascular events were registered (cardiovascular deaths 70; non-fatal myocardial infarction 46). Baseline adiponectin concentrations were similar in patients presenting with SAP [9.03 microg/mL (6.7, 13.45)] or ACS [9.19 microg/mL (6.72, 13.15)], P = 0.779. Kaplan-Meier survival analysis showed a stepwise decrease in event-free survival across quartiles of adiponectin baseline concentration (P log rank = 0.0188). A similar pattern was observed in both subgroups of patients (SAP P = 0.075 and ACS P = 0.254). In univariate analyses, continuous adiponectin concentration was related to event-free survival in all patients [HR 1.02 (95% confidence interval 1.0-1.04), P = 0.012] as well as in the subgroup of SAP subjects [1.03 (1.01-1.05), P = 0.012]. The relation was less strong in the subgroup presenting with ACS [1.014 (0.99-1.04), P = 0.280]. A correlation of adiponectin with high density cholesterol (r = 0.39) and a negative relation to triglyceride levels (r = -0.22) could be described. An increase of one interquartile distance in adiponectin concentration was associated with a 1.17-fold risk for future cardiovascular events (P = 0.013), in B-type natriuretic peptide (BNP) it meant a 1.13-fold risk (P < 0.001). In the overall patient group, this risk association remained robust after the adjustment for classical risk factors, clinical presentation and cardiac medication. Only after adjustment for BNP adiponectin lost its independent predictive value. CONCLUSION: In contrast to studies including initially healthy individuals, the current prospective study demonstrates that adiponectin is associated with adverse cardiovascular outcome in patients with manifest CAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176
Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure
Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., & Hildebrandt, P. (2005) · Circulation · doi:10.1161/circulationaha.104.530972 · Cited by 605 · cited 1×
“A strong correlation with Nt-proBNP in chronic heart failure patients had been described earlier.(16) These findings suggest that the relation of these two biomarkers seen in these groups may in fact be due to the association between adiponectin and left ventricular dysfunction and/or congestive heart failure which ha…”
BackgroundAdiponectin and Coronary Heart Disease: The Strong Heart Study
Lindsay, R. S., Resnick, H. E., Zhu, J., Tun, M. L., Howard, B. V., Zhang, Y., Yeh, J., & Best, L. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000153090.21990.8c · Cited by 169 · cited 1×
“In the Strong Heart Study (SHS), no significant association with later development of CAD could be found in American Indians which has been explained by the potential impact of a higher prevalence of diabetes mellitus in this study cohort.(13) Furthermore, ethnic differences in adiponectin levels have to be considered…”
BackgroundKoenig, W., Khuseyinova, N., Baumert, J., Meisinger, C., & Löwel, H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.053 · Cited by 166
von Eynatten, M., Hamann, A., Twardella, D., Nawroth, P. P., Brenner, H., & Rothenbacher, D. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.060509 · Cited by 140
Cited by
Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients With COPD
Waschki, B., Kirsten, A., Holz, O., Müller, K.-C., Meyer, T., Watz, H., & Magnussen, H. (2011) · Chest · doi:10.1378/chest.10-2521 · Cited by 951
Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease
Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., & Després, J.-P. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.110320 · Cited by 490
Obesity, Inflammation, and Cardiovascular Risk
Mathieu, P., Lemieux, I., & Després, J.-P. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.311 · Cited by 419
APPL1: role in adiponectin signaling and beyond
Deepa, S. S., & Dong, L. Q. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90731.2008 · Cited by 287
Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome
Kita, S., Maeda, N., & Shimomura, I. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129193 · Cited by 273
Metadata
- Authors
- Schnabel, R., Messow, C. M., Lubos, E., Espinola-Klein, C., Rupprecht, H. J., Bickel, C., Sinning, C., Tzikas, S., Keller, T., Genth-Zotz, S., Lackner, K. J., Munzel, T. F., & Blankenberg, S.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 29
- Issue
- 5
- Pages
- 649-657
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2131400699
- Cited by
- 130
- References
- 6
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. https://app.cochat.ai/papers/10.1093/eurheartj/ehn009
- The paper
- Schnabel, R., Messow, C. M., Lubos, E., Espinola-Klein, C., Rupprecht, H. J., Bickel, C., Sinning, C., Tzikas, S., Keller, T., Genth-Zotz, S., Lackner, K. J., Munzel, T. F., & Blankenberg, S. (2008). Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehn009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.